Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147593 | 0.88 | FAAH (0.47) | FAAHALDH1A1 | |
| SCHEMBL13850444 | 0.87 | SLC2A1 (0.45) | SLC2A1MEN1KMT2AGPR119JAK2 | |
| SCHEMBL2766618 | 0.85 | GPR119 (0.58) | SLC2A1GPR119YAP1 | |
| SCHEMBL13849603 | 0.81 | EPHX2 (0.39) | SLC2A1GPR119JAK2JAK1EPHX2 | |
| SCHEMBL13849585 | 0.81 | ROCK1 (0.40) | FAAHALDH1A1 | |
| SCHEMBL24302338 | 0.80 | GPR119 (0.50) | MEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL31457748 | 0.80 | GPR119 (0.53) | SLC2A1GPR119YAP1 | |
| SCHEMBL13850446 | 0.78 | CCR5 (0.49) | KMT2AEPHX2ALDH1A1 | |
| SCHEMBL15115095 | 0.78 | GPR119 (0.54) | MEN1KMT2AGPR119EPHX2STS | |
| SCHEMBL28467850 | 0.76 | CHRNB2 (0.56) | KMT2AFAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | SLC2A1 747/4885MEN1 488/4885KMT2A 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.